Fuelled by Pfizer, Triana enters the clinic
The industry’s first ALK degrader starts its first human study.
SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
Gilead buys what it tried with Tubulis
A $3.15bn deal follows a December 2024 option agreement.
Licensing analysis: Chinese deals abound
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
Oric gets a reality check
Rinzimetostat efficacy wanes further as the company moves into phase 3.
FDA red and green lights: March 2026
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
